Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.50 |
| ▸ | AKT2 | P31751 | 6/20 | 0.49 |
| ▸ | JAK3 | P52333 | 5/20 | 0.48 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079062 | 0.84 | JAK3 (0.61) | AKT1AKT2JAK3PBKJAK1 | |
| SCHEMBL10277773 | 0.82 | JAK3 (0.66) | AKT1AKT2JAK3JAK1JAK2 | |
| SCHEMBL30009218 | 0.82 | JAK1 (0.64) | AKT1AKT2JAK3PBKJAK1 | |
| SCHEMBL1080253 | 0.80 | KIT (0.47) | AKT1AKT2JAK3JAK1JAK2 | |
| SCHEMBL30009396 | 0.80 | AKT1 (0.54) | AKT1AKT2JAK3PBKJAK1 | |
| SCHEMBL16026477 | 0.80 | AKT2 (0.59) | AKT1AKT2PBKGSK3BNUDT1 | |
| SCHEMBL30009292 | 0.78 | AKT1 (0.52) | AKT1AKT2JAK3PBKJAK1 | |
| SCHEMBL1078983 | 0.77 | JAK3 (0.53) | JAK3JAK2 | |
| SCHEMBL27879392 | 0.75 | AKT1 (0.57) | AKT1AKT2JAK3PBKJAK1 | |
| SCHEMBL4934159 | 0.74 | JAK1 (0.53) | AKT1AKT2JAK3PBKJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | claimed |
| CN-102574857-B | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors | LEO PHARMA AS | 2015-06-10 | — | — | CN | claimed |
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | claimed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | claimed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| CN-102574857-B | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors | LEO PHARMA AS | 2015-06-10 | — | — | CN | disclosed |
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | AKT1 290/4885AKT2 703/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.